CERo Therapeutics Holdings, Inc. Common Stock
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
CERo Therapeutics Holdings, Inc. Common Stock (CERO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.705x
Based on the latest financial reports, CERo Therapeutics Holdings, Inc. Common Stock (CERO) has a cash flow conversion efficiency ratio of 0.705x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.21 Million) by net assets ($-4.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CERo Therapeutics Holdings, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how CERo Therapeutics Holdings, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
CERo Therapeutics Holdings, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CERo Therapeutics Holdings, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thai Textile Industry Public Company Limited
BK:TTI
|
-0.021x |
|
Anagenics Ltd
AU:AN1
|
-0.286x |
|
Public Service Company of New Mexico PFD 4.58%
PINK:PNMXO
|
-0.016x |
|
Kedaung Indah Can Tbk
JK:KICI
|
-0.009x |
|
Lehto Group Oyj
F:L7G
|
12.566x |
|
Goldflare Exploration Inc
V:GOFL
|
-0.052x |
|
Silly Monks Entertainment Limited
NSE:SILLYMONKS
|
0.107x |
|
Irwin Naturals, Inc.
PINK:IWINQ
|
0.079x |
Annual Cash Flow Conversion Efficiency for CERo Therapeutics Holdings, Inc. Common Stock (2021–2024)
The table below shows the annual cash flow conversion efficiency of CERo Therapeutics Holdings, Inc. Common Stock from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-1.89 Million | $-5.79 Million | 3.056x | +2119.92% |
| 2023-12-31 | $-42.06 Million | $-5.79 Million | 0.138x | +131.12% |
| 2022-12-31 | $2.47 Million | $-1.09 Million | -0.442x | -10742.21% |
| 2021-12-31 | $170.83 Million | $-697.11K | -0.004x | -- |